Birth

EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

Retrieved on: 
金曜日, 5月 10, 2024
Birth, FDA, Phase, Pneumonia, Grifols, Technology transfer, Dreieich, Management, Fibrinogen, Immunodeficiency, Collection, Research, Community-acquired pneumonia, Factor, Biologics license application, ROCE, SCAP, Tax, Patient, Next Level, Health, Plasma, Disclosure, Video game

The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year.

Key Points: 
  • The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year.
  • EBIT for the first quarter of 2024 amounted to € 52.8 million, a significant improvement on the first quarter of the previous year (prior year period: € - 9.1 million).
  • The financial result for the first quarter of the current year deteriorated by € -1.4 million to € -10.7 million (prior-year period: € -9.3 million).
  • The Biotest Group's earnings after taxes improved to € 29.5 million in the first quarter of 2024 after € -20.4 million in the same quarter of the previous year due to the influencing factors described above.

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
火曜日, 5月 7, 2024
Birth, FDA, Capsule, Myelokathexis, Research and development, Priority review, Safety, WHIM syndrome, Food, Security (finance), Conference call, WHIM, Research, Conference, Wart, Neutrophil, CIS, Patient, Society, EMA, Hypogammaglobulinemia, Infection, G-CSF, Interim, Immune system, Lymphocyte, Clinical trial, ID, European Medicines Agency, Pharmaceutical industry

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones.
  • “Concurrent with this approval, we received a Rare Pediatric Disease Priority Review Voucher, which we intend to monetize.
  • X4 currently expects to seek approval from the European Medicines Agency (EMA) for mavorixafor in WHIM syndrome in late 2024/early 2025.
  • The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com.

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
木曜日, 5月 9, 2024
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Birth, Administration, DSM-IV codes, Corporation, Pregnancy, Risk, Safety, Pharmacokinetics, Publication, Iron overload, Johnson & Johnson, Gestational age, Data, Research and development, Patient, Marker beacon, Caregiver, Workforce, G&A, Pharmaceutical industry

Rallybio is on track to initiate a Phase 2 trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT in the second half of 2024.

Key Points: 
  • Rallybio is on track to initiate a Phase 2 trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT in the second half of 2024.
  • Rallybio expects to provide an update on this analysis and future development plans for RLYB116 in the second half of 2024.
  • Net Loss and Net Loss Per Common Share: Rallybio reported a net loss of $19.0 million, or $0.47 per common share, for the first quarter of 2024.
  • This compares to a net loss of $17.3 million, or $0.43 per common share, for the first quarter of 2023.

SENATOR LENA GONZALEZ AND THE CAMPAIGN FOR A SAFE AND HEALTHY CALIFORNIA CALL ON LEGISLATURE TO INVESTIGATE POTENTIAL TAX AND LEGAL LOOPHOLES EXPLOITED BY BIG OIL

Retrieved on: 
水曜日, 5月 8, 2024
Public, Cancer, United States Senate, Safety, Hospital, ExxonMobil, State, Big Oil, Health, School, Deception, Legislature, Election, Senate, Disclosure, History, Tax, Campaign, Petroleum, Committee, Multimedia, BP, Birth, Valero, Letter, LAW, Amendment

SACRAMENTO, Calif., May 8, 2024 /PRNewswire/ -- As Big Oil continues to spend more than $60 million on a misinformation campaign, lying to voters about the public health benefits of keeping a law (SB 1137 - Senator Lena Gonzalez) that protects communities from toxic oil and gas drilling, the Campaign for a Safe and Healthy California and Senator Lena Gonzalez are calling on the State Legislature to investigate a shady tactic Big Oil is employing to fund their campaign of deception.

Key Points: 
  • Despite record breaking profits, fourteen oil companies avoided making direct contributions to their campaign to overturn Senator Gonzalez's law to keep California schools and neighborhoods safe from toxic drilling (SB 1137).
  • "I am calling on my colleagues in the Legislature to investigate this practice and close any loopholes we find."
  • Big Oil has a history of obfuscating how and where they are spending money on political campaigns.
  • For more information about our campaign, please visit our website at: www.CAvsBigOil.com
    Paid for by Campaign for a Safe and Healthy California, sponsored by nonprofit environmental and health organizations.

Hand to Hold® launches national NICU Graduate Then & Now Photo Contest to kick off graduation season

Retrieved on: 
火曜日, 5月 7, 2024
NICU, Infant, CST, Secondary school, US1, Love, Elementary, Parent, Neonatal intensive care unit, Rich, Child, Ventricular septal defect, Class, Birth, Middle school, Premature, Calendar, Entertainment

AUSTIN, Texas, May 7, 2024 /PRNewswire/ -- Hand to Hold, a national nonprofit that provides early intervention mental health support for Neonatal Intensive Care Unit (NICU) parents before, during and after the NICU has announced its 2024 NICU Grad Then & Now Photo Contest. The contest opens at 9:00 a.m. (CST) on May 7, 2024 and closes on May 17, 2024 at 10:00 p.m. (CST). The contest is free to enter and open to all NICU graduates of any age in the U.S. and Canada.

Key Points: 
  • The contest is free to enter and open to all NICU graduates of any age in the U.S. and Canada.
  • Hand to Hold celebrates & unites NICU families with annual contest while raising funds to ensure support remains free.
  • It was an amazing opportunity to spread awareness about the many resources Hand to Hold offers to NICU parents.
  • Hand to Hold created this national annual celebration to unite NICU families while raising funds to ensure support services remain free to all NICU and bereaved families.

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Retrieved on: 
火曜日, 4月 23, 2024
FDA, LARC, Woman, Levonorgestrel, Software, Diabetes, Communication, Fertility, Birth, Osteoporosis, Obesity, Human, Patient, Electronics, DSM-IV codes, Condition, Investigational New Drug, Injection, Pharmaceutical industry

SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Daré’s investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug (IND) Application with the FDA, approval of which will be required to commence testing in humans. Under the terms of the grant agreement, Daré may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1. To date, Daré has received payments totaling approximately $28.3 million. Additional payments are conditioned on the program meeting specified development and reporting milestones.

Key Points: 
  • Under the terms of the grant agreement, Daré may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1.
  • Additional payments are conditioned on the program meeting specified development and reporting milestones.
  • “The DARE-LARC1 product candidate is one of a number of novel contraceptive technologies being developed by Daré,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • To support development opportunities outside of the reproductive health category, including diabetes, obesity, and other conditions requiring precise and prolonged treatment, Daré is exploring strategic discussions with potential industry partners.

Health Advocate Applauds Federal Budget 2024 in providing costing on a National Pharmacare Plan; a milestone in universal free access to contraceptives

Retrieved on: 
水曜日, 4月 17, 2024
Public, Woman, Policy, Reproductive rights, Intrauterine device, Birth, Workforce, Government, Birth control

This represents a generational shift when it comes to women’s health care in Canada.

Key Points: 
  • This represents a generational shift when it comes to women’s health care in Canada.
  • Access to contraception is not only a matter of reproductive rights but also a fundamental aspect of public health and equity.
  • Time is of the essence here in Canada, but also when reflecting on the threats to women’s health care globally.
  • “The SOGC is pleased with today’s funding commitments in Budget 2024- an important milestone toward universal free access to contraception to all Canadian women.

16-Time Gold Medalist Paralympic Swimmer Jessica Long and her Goldendoodle Goose Partner with Nulo

Retrieved on: 
火曜日, 4月 23, 2024
Retail, Other Consumer, Swimming, Women, Olympics, Online Retail, Sports, Pets, Other Retail, Men, People with Disabilities, Specialty, Family, Lifestyle, Food, Beverage, Consumer, Multimedia, Health, Paralympic Games, Courage, Partnership, Life, Hope, Pet, Birth, Incredible, Gold, Athlete

Nulo is proud to partner with Jessica Long, one of the most decorated Paralympians in American history, and her Goldendoodle, Goose, to champion its "Fuel Incredible" campaign.

Key Points: 
  • Nulo is proud to partner with Jessica Long, one of the most decorated Paralympians in American history, and her Goldendoodle, Goose, to champion its "Fuel Incredible" campaign.
  • View the full release here: https://www.businesswire.com/news/home/20240423208016/en/
    16-time Gold medalist Paralympian Jessica Long shares a heartwarming moment with her loyal companion, Goose, who is always there to lift her spirits and lend emotional support.
  • Alongside Jessica in her current journey is Goose, a rescue dog who helps her be at her best.
  • Reflecting on Goose's role in her life, Jessica shared, “Goose brings such amazing energy and joy to my life.

What Women Can Do to Take Control of Their Reproductive Health & Rights Post-Roe, according to Mary Jane Minkin, M.D.

Retrieved on: 
水曜日, 4月 17, 2024
Women, FDA, Baby, Maternity, Convenience Store, Health, Consumer, Pharmaceutical, General Health, Retail, Education, Medroxyprogesterone acetate, Roe v. Wade, 7-Eleven, LARC, Misoprostol, Condom, Safety, Pregnancy, Woman, Cadence, Policy, Supreme court, OTC, Mini, Planned Parenthood, Mifepristone, Reproductive rights, Abortion, Uterus, Yale University, Arm, Birth, Parenthood, Reproductive Sciences, Long-acting reversible contraceptives, Confidentiality, Progesterone, Pharmacy, Birth control

Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University, stresses the critical need for accessible contraception and reproductive health tools to prevent unintended pregnancies.

Key Points: 
  • Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University, stresses the critical need for accessible contraception and reproductive health tools to prevent unintended pregnancies.
  • "The rollback on reproductive rights makes it absolutely imperative that we prioritize comprehensive access to contraception," says Dr. Minkin.
  • "It's not just about preventing pregnancy; it's about preserving the autonomy and health of women across the nation."
  • "We must ensure that women of all ages have the education, resources, and confidentiality to make informed choices about their reproductive health.

Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

Retrieved on: 
月曜日, 4月 15, 2024
Science, Other Science, Research, Oncology, Health, Medical Devices, Health Technology, Genetics, DSM-IV codes, Cytogenetics, Agilent Technologies, Safety, Certification, Birth, Pregnancy, Edible frog, Patient, Genome, Intellectual disability, European, Chromosome, IVDR, Comparative genomic hybridization, COVID-19, Medical device

Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.
  • This certification demonstrates that the assay meets the higher standards established by IVDR.
  • “The GenetiSure Dx Postnatal Assay will advance the postnatal diagnosis of chromosomal abnormalities, as it combines high resolution, accuracy, and speed in a single test.
  • With the European IVDR Class C Certification, we are confident that this assay will continue to serve the needs of healthcare professionals and their patients across the EU.”
    Jenipher Dalton, chief quality and regulatory officer at Agilent, summarized the announcement’s significance.